Magellan Rx first to innovate with Medicaid VBC solutions for states grappling with the high cost of novel cell and gene therapies

Prime celebrates 25th anniversary, and Magellan Rx celebrates 10th anniversary

In late 2023, the FDA approved a new treatment regimen for urothelial cancer that represents a “paradigm change,” according to one industry expert

Nicole Grevenitz, director of clinical account services, shares more from the research study “Promoting Health Equity Through Enhanced, Personalized Digital Outreach.”

Meredith Delk, senior vice president and general manager of state government solutions at Prime Therapeutics, shares more about the important role women play in our world today

Scott Leslie, director of health outcomes, shares more about the study “Real-World Case Series Study of Spinal Muscular Atrophy Pediatric Patients Treated With Onasemnogene Abeparvovec (Zolgensma)”

A look at the specialty landscape and how Prime delivers value to employers

What works and what doesn’t